Crossmark

Subkutanes Infliximab in der CED-Therapie

Crossref DOI link: https://doi.org/10.1007/s15036-024-3723-7

Published Online: 2024-06-18

Published Print: 2024-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Facharztmagazine, Redaktion
License Information

Text and Data Mining valid from 2024-06-01

Version of Record valid from 2024-06-01
More Information

Article History

First Online: 18 June 2024

Free to read: This content has been made available to all.